Neurocysticercosis Treatment Guidelines

Initial Evaluation and Diagnosis

The Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH) recommend initial evaluation to include careful history, physical examination, and neuroimaging studies with both brain MRI and non-contrast CT scan 1
Serologic testing with enzyme-linked immunotransfer blot is recommended as a confirmatory test, avoiding ELISA using crude antigen due to poor sensitivity and specificity, as suggested by the IDSA 1
The IDSA recommends all patients undergo fundoscopic examination prior to initiation of anthelmintic therapy to rule out retinal involvement 1

The IDSA suggests screening for latent tuberculosis infection in patients likely to require prolonged corticosteroids 1
Screening for or empirically treating Strongyloides stercoralis is recommended in patients likely to require prolonged corticosteroids, according to the IDSA 1
Household members of patients who acquired neurocysticercosis in non-endemic areas should be screened for tapeworm carriage, as recommended by the IDSA 1

For patients with 1-2 viable parenchymal cysticerci, the IDSA recommends albendazole monotherapy for 10-14 days at 15 mg/kg/day (maximum 1200 mg/day) divided into 2 daily doses with food 1
For patients with >2 viable parenchymal cysticerci, combination therapy with albendazole (15 mg/kg/day) plus praziquantel (50 mg/kg/day) for 10-14 days is suggested by the IDSA and the American Society of Tropical Medicine and Hygiene (ASTMH) 2
Corticosteroids should be initiated prior to antiparasitic therapy to reduce inflammatory response, as recommended by the IDSA 1
If cystic lesions persist for 6 months after initial treatment, retreatment with antiparasitic therapy is suggested by the IDSA and the ASTMH 2
The IDSA recommends MRI to be repeated at least every 6 months until resolution of cystic component 1

For elevated intracranial pressure, the IDSA recommends managing elevated intracranial pressure first before antiparasitic treatment, using anti-inflammatory therapy (corticosteroids) for diffuse cerebral edema and surgical approach for hydrocephalus 1
Patients treated with albendazole for >14 days should be monitored for hepatotoxicity and leukopenia, as suggested by the IDSA 1

Albendazole should be administered at 15 mg/kg/day divided into 2 daily doses for 10-14 days with food (maximum 1200 mg/day), according to the IDSA 1
Praziquantel should be used at 50 mg/kg/day when used in combination therapy, as recommended by the IDSA and the ASTMH 2
Important drug interactions include praziquantel interacting with steroids, decreasing its serum concentrations, and serum levels of phenytoin and carbamazepine may be lowered by praziquantel, as noted in Clinical Microbiology Reviews 3

The IDSA suggests that diagnosis and management of neurocysticercosis can be challenging, and clinicians with little experience should consult with disease experts 1
Attempted removal of inflamed or adherent ventricular cysticerci is associated with increased risk of complications, as noted by the IDSA and the ASTMH 2
The choice of antiepileptic drugs should be guided by local availability, cost, drug interactions, and potential side effects, according to the IDSA and the ASTMH 2

Adults with 1–2 viable parenchymal cysts should receive albendazole 15 mg/kg/day (maximum 1200 mg) divided twice daily with food for 10 days. [IDSA/ASTMH guideline] 4
Adults with more than 2 viable parenchymal cysts should receive combination therapy: albendazole 15 mg/kg/day (maximum 1200 mg) plus praziquantel 50 mg/kg/day divided three times daily for 10–14 days. [IDSA/ASTMH guideline] 4
The 2018 IDSA/ASTMH guidelines supersede older protocols that used variable treatment durations of 8–30 days. 4
For a single enhancing lesion, a shorter course of 1–2 weeks of albendazole 15 mg/kg/day (maximum 800 mg) is sufficient. 4

Corticosteroids must be started before or simultaneously with antiparasitic therapy to prevent life‑threatening cerebral edema from dying parasites. 4
Recommended regimens are dexamethasone 4.5–12 mg/day or prednisone 1 mg/kg/day for short‑term therapy. 5
Neurological symptoms commonly worsen between days 2–5 of antiparasitic treatment due to an inflammatory response; this is managed with steroids rather than stopping therapy. 6
In massive infections or severe cerebral edema, dexamethasone doses up to 32 mg/day may be required. 7

Perform a fundoscopic examination before initiating albendazole to exclude intra‑ocular cysticerci, as antiparasitic therapy can cause blindness in ocular disease. 4
Screen patients from endemic areas for Strongyloides stercoralis (or treat empirically with ivermectin) before prolonged corticosteroid use to prevent hyperinfection syndrome. 4

Praziquantel concentrations are reduced when co‑administered with corticosteroids, although clinical parasiticidal efficacy appears unchanged. 6
Praziquantel lowers serum levels of phenytoin and carbamazepine; antiepileptic drug levels should be monitored and doses adjusted as needed. 6
Albendazole does not interact with corticosteroids and maintains stable CSF penetration. 6
Albendazole should always be taken with food to enhance absorption. 4

All patients presenting with seizures should start antiepileptic drugs and continue them for at least 2 years if seizure‑free. 4
Antiepileptics may be discontinued after cyst resolution only when no risk factors are present: no residual calcifications on CT, no breakthrough seizures during treatment, and ≤2 total seizures during the disease course. 4
Residual calcifications on follow‑up CT identify patients at high risk for recurrent seizures, warranting longer‑term antiepileptic therapy. 7

Praziquantel monotherapy (50 mg/kg/day for 15 days) is an alternative when albendazole is unavailable or contraindicated, although albendazole is preferred because of better CSF penetration and lower cost. 6
A single‑day high‑dose praziquantel regimen (75 mg/kg) has been used but is less well‑studied. 6

Calcified lesions do not require antiparasitic therapy because no viable parasites are present. 4
Patients with massive infections (e.g., >100 cysts) have a higher mortality risk and should receive specialist consultation. 7